In ER + breast cancer patients who received endocrine therapy, low RPA1 was associated with shorter BCSS (P < 0.0001) (Fig. 1E) and DMFS (P < 0.0001) (Supplementary Fig. 1F) suggesting that low RPA expression may predict limited response to endocrine therapy. The gene discussed is RPA1; the disease is breast carcinoma.